Graft Versus Host Disease (GVHD)

Prevention
- BMT304
  Phase II
  Obinutuzumab in Prevention of cGVHD After Allogeneic Peripheral Blood Stem Cell Transplant
  PI: Miklos Dana Farber
- BMT329
  Phase II Defibrotide Added vs SoC Immunophrophaxis in Prevention of AGVHD After Allogeneic HSCT
  PI: Arai Pending
- VAR0158
  Phase I Pirfenidone for Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
  PI: Hsu Stanford
- BMT350
  Phase II KD025 in Chronic Graft Versus Host Disease After 2 Prior Lines of Systemic Therapy
  PI: Arai Sponsor: Kadmon

Chronic
- BMT311
  Phase III Ibrutinib Combo w/ Corticosteroids vs Placebo Combo w/ Corticosteroids in New Onset cGVHD
  PI: Miklos Pharmacies

New Onset
- BMT327
  Phase III Ibrutinib or Placebo +/- Corticosteroids in First-Line Acute Graft-Versus-Host Disease Tx
  PI: Meyer Incyte Corporation

Acute
- BMT267
  Phase I Primary T Regulatory Cell Tx to Treat Visceral Acute GVHD After HCT
  PI: Meyer Stanford

Diagnostic
- BMT323
  Detection of GVHD w/ [18]F-F-D Ara-G, a Positron Emission Tomography Tracer for Activated T Cells
  PI: Gambhir Stanford

Within 3 days of Steroid Treatment

Key:
- Pending
- Open for Enrollment
- Link
- Optional Path
- Extension Study
- Immunotherapy